SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-157521
Filing Date
2024-06-07
Accepted
2024-06-07 17:07:30
Documents
17
Period of Report
2024-06-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d835355d8k.htm   iXBRL 8-K 29201
2 EX-1.1 d835355dex11.htm EX-1.1 189472
3 EX-5.1 d835355dex51.htm EX-5.1 13671
7 GRAPHIC g835355g0607134927174.jpg GRAPHIC 1756
8 GRAPHIC g835355g62s37.jpg GRAPHIC 3845
  Complete submission text file 0001193125-24-157521.txt   426802

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA fdmt-20240607.xsd EX-101.SCH 2898
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE fdmt-20240607_lab.xml EX-101.LAB 18737
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fdmt-20240607_pre.xml EX-101.PRE 11739
20 EXTRACTED XBRL INSTANCE DOCUMENT d835355d8k_htm.xml XML 3771
Mailing Address 5858 HORTON STREET #455 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET #455 EMERYVILLE CA 94608 5105052680
4D Molecular Therapeutics, Inc. (Filer) CIK: 0001650648 (see all company filings)

IRS No.: 473506994 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39782 | Film No.: 241030575
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)